NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
| Revenue (TTM) | $699.19M |
| Gross Profit (TTM) | $533.98M |
| EBITDA | $-136.39M |
| Operating Margin | -5.75% |
| Return on Equity | -43.20% |
| Return on Assets | -9.26% |
| Revenue/Share (TTM) | $6.16 |
| Book Value | $2.85 |
| Price-to-Book | 6.05 |
| Price-to-Sales (TTM) | 2.82 |
| EV/Revenue | 2.627 |
| EV/EBITDA | -6.92 |
| Quarterly Earnings Growth (YoY) | -6.00% |
| Quarterly Revenue Growth (YoY) | 15.60% |
| Shares Outstanding | $115.82M |
| Float | $95.84M |
| % Insiders | 9.96% |
| % Institutions | 86.94% |
Volatility is currently expanding
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
NovoCure remains a Hold as recent gains and operational improvements do not alter its long-term, glioblastoma-centric outlook. Q2 revenue grew 16% Y/Y to $183.6M, with adjusted EBITDA guidance raised to $0–$15M, yet true cash generation remains elusive. Optune Pax's early uptake is promising but too preliminary to signal sustainable growth; its Q2 contribution was just $1.6M.
Novocure (NVCR) delivered a strong 2Q26 beat, raising full-year guidance to $710–$725 million and achieving positive adjusted EBITDA, signaling a credible path to profitability. NVCR's operating leverage is improving, with gross margins at 78% and net loss narrowing significantly, driven by 18% global active patient growth and expanding indications. Optune Pax's early launch shows promising adoption across academic and community settings, with repeat prescribing indicating potential for durable utilization and revenue upside.
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago.
NovoCure NASDAQ: NVCR reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance.
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was our strongest quarter to date, with record net revenues and active patients on therapy,” said Frank Leonard, CEO, Novocure. “We continue to lau.
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVCR and any ticker you trade — then tracks every position and per-strategy win rate.
